Hibbard D M, Peters J R, Hunninghake D B
Br J Clin Pharmacol. 1984 Sep;18(3):337-42. doi: 10.1111/j.1365-2125.1984.tb02473.x.
The effect of equivalent hypolipidaemic doses of cholestyramine (8 g) or colestipol (10 g) on the plasma concentrations of propranolol and 4'-hydroxypropranolol was studied in 12 normal volunteers following the oral administration of 120 mg of normal release propranolol tablets. When two doses of either cholestyramine or colestipol were administered prior to the propranolol, the peak plasma concentrations and area under the curve for both propranolol and the metabolite 4'-hydroxypropranolol were reduced significantly (P less than 0.05). We conclude that the drug interaction between cholestyramine or colestipol and propranolol leads to significant reductions in plasma concentrations of propranolol and 4'-hydroxypropranolol which may cause a clinically diminished effect for a given dosage. Therefore, patients should be observed when either of these resins are added to or deleted from a therapeutic regimen.
在12名正常志愿者口服120mg普通释放型普萘洛尔片后，研究了等效降血脂剂量的消胆胺（8g）或考来替泊（10g）对普萘洛尔和4'-羟基普萘洛尔血浆浓度的影响。当在普萘洛尔之前给予两剂消胆胺或考来替泊时，普萘洛尔及其代谢物4'-羟基普萘洛尔的血浆峰值浓度和曲线下面积均显著降低（P<0.05）。我们得出结论，消胆胺或考来替泊与普萘洛尔之间的药物相互作用导致普萘洛尔和4'-羟基普萘洛尔的血浆浓度显著降低，这可能会使给定剂量的临床效果减弱。因此，当这些树脂中的任何一种添加到治疗方案中或从治疗方案中去除时，都应对患者进行观察。
